WO2013089394A3 - 고분자 나노입자 수용액 조성물 및 그 제조방법 - Google Patents

고분자 나노입자 수용액 조성물 및 그 제조방법 Download PDF

Info

Publication number
WO2013089394A3
WO2013089394A3 PCT/KR2012/010637 KR2012010637W WO2013089394A3 WO 2013089394 A3 WO2013089394 A3 WO 2013089394A3 KR 2012010637 W KR2012010637 W KR 2012010637W WO 2013089394 A3 WO2013089394 A3 WO 2013089394A3
Authority
WO
WIPO (PCT)
Prior art keywords
aqueous solution
pharmaceutical composition
composition
preparing same
polymeric nanoparticles
Prior art date
Application number
PCT/KR2012/010637
Other languages
English (en)
French (fr)
Other versions
WO2013089394A2 (ko
Inventor
이사원
조중웅
김경해
서민효
Original Assignee
주식회사 삼양바이오팜
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 삼양바이오팜 filed Critical 주식회사 삼양바이오팜
Priority to US14/362,234 priority Critical patent/US9522190B2/en
Priority to EP12857983.6A priority patent/EP2792348B1/en
Priority to CN201280061834.2A priority patent/CN104010627A/zh
Publication of WO2013089394A2 publication Critical patent/WO2013089394A2/ko
Publication of WO2013089394A3 publication Critical patent/WO2013089394A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)

Abstract

수용액 상태에서 안정성이 향상된 고분자 약물 담체 함유 약학적 조성물 및 이의 안정화 방법이 개시된다. 더욱 구체적으로, 친수성 블록과 소수성 블록으로 구성된 양친성 블록 공중합체 및 말단 카르복시기에 2가 또는 3가 금속이온이 고정된 폴리락트산 유도체를 포함하는 고분자 약물 담체를 함유하며 냉장보관 시 6개월 이상, 바람직하게는 12개월 이상 보존 안정성이 유지되는 약학적 수용액 조성물 및 이의 안정화 방법이 개시된다.
PCT/KR2012/010637 2011-12-16 2012-12-07 고분자 나노입자 수용액 조성물 및 그 제조방법 WO2013089394A2 (ko)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US14/362,234 US9522190B2 (en) 2011-12-16 2012-12-07 Polymeric nanoparticle solution composition and its manufacturing process
EP12857983.6A EP2792348B1 (en) 2011-12-16 2012-12-07 Composition of an aqueous solution of polymeric nanoparticles and method for preparing same
CN201280061834.2A CN104010627A (zh) 2011-12-16 2012-12-07 高分子纳米粒子水溶液组合物及其制备方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20110136809A KR101508275B1 (ko) 2011-12-16 2011-12-16 고분자 나노입자 수용액 조성물 및 그 제조방법
KR10-2011-0136809 2011-12-16

Publications (2)

Publication Number Publication Date
WO2013089394A2 WO2013089394A2 (ko) 2013-06-20
WO2013089394A3 true WO2013089394A3 (ko) 2013-08-08

Family

ID=48613314

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/010637 WO2013089394A2 (ko) 2011-12-16 2012-12-07 고분자 나노입자 수용액 조성물 및 그 제조방법

Country Status (5)

Country Link
US (1) US9522190B2 (ko)
EP (1) EP2792348B1 (ko)
KR (1) KR101508275B1 (ko)
CN (1) CN104010627A (ko)
WO (1) WO2013089394A2 (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102150729B1 (ko) * 2013-12-31 2020-09-01 도레이첨단소재 주식회사 분리막용 보존용액 조성물, 이를 포함하는 보존용액 및 이를 포함하는 분리막
WO2016049250A1 (en) * 2014-09-24 2016-03-31 The Board Of Trustees Of The University Of Illinois Artificial platelets for treating catastrophic bleeding
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR101745429B1 (ko) * 2015-07-28 2017-06-12 주식회사 삼양바이오팜 양친성 블록 공중합체의 정제방법, 이로부터 얻어지는 양친성 블록 공중합체, 및 이를 포함하는 약학 조성물
PT3391875T (pt) * 2015-12-18 2021-12-20 Samyang Holdings Corp Método para preparar micelas poliméricas contendo fármaco aniónico
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
KR101971672B1 (ko) * 2016-11-18 2019-04-23 주식회사 삼양바이오팜 화학색전용 에멀전 조성물 및 그의 제조방법
EP3654948A4 (en) * 2017-07-17 2020-12-09 Children's Hospital Medical Center POLYETHYLENIMINNANO PARTICLES AND METHOD FOR THEIR USE
US10457772B2 (en) 2017-09-08 2019-10-29 International Business Machines Corporation Preparation of robust polythioaminal carriers
CN107441061B (zh) * 2017-09-29 2021-02-05 长春金赛药业有限责任公司 黄体酮缓释纳米粒、其制备方法和黄体酮缓释注射剂
BR112021002126A2 (pt) * 2018-08-07 2022-01-25 Samyang Biopharmaceuticals Composição para dispensação de vírus, e, método para preparação de uma composição para dispensação de vírus.
WO2020067731A1 (ko) * 2018-09-28 2020-04-02 주식회사 삼양바이오팜 면역원성 세포사멸 유도 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100560069B1 (ko) * 2002-11-29 2006-03-13 주식회사 태평양 생분해성 양친성 블록공중합체 및 이의 제조방법
KR100704548B1 (ko) * 2005-10-31 2007-04-09 한국과학기술연구원 염증 부위 특이적 고분자 유도체 및 그의 용도
KR100703872B1 (ko) * 2003-10-10 2007-04-09 주식회사 삼양사 양친성 블록 공중합체 및 이를 포함하는 약물 전달용고분자 조성물
KR20100057007A (ko) * 2007-07-09 2010-05-28 글렌 에스. 권 치료제의 마이셀 캡슐화

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674837A (en) * 1994-08-01 1997-10-07 Abbott Laboratories Stable bleomycin sulfate solution suitable for injection
CA2463172C (en) * 2001-10-18 2009-08-18 Samyang Corporation Polymeric micelle composition with improved stability
CA2463517C (en) 2001-10-18 2010-03-16 Samyang Corporation Ph responsive biodegradable polylactic acid derivatives forming polymeric micelles and uses thereof for poorly water soluble drug delivery
KR100531269B1 (ko) * 2001-12-04 2005-11-28 주식회사 삼양사 수용액에서 안정한 미셀 또는 나노 파티클을 형성하는고분자 조성물
CN100471886C (zh) * 2003-10-10 2009-03-25 株式会社三养社 两亲嵌段共聚物以及包含它的用于给药的聚合组合物
US7311901B2 (en) 2003-10-10 2007-12-25 Samyang Corporation Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
GR1005154B (el) * 2005-02-09 2006-03-13 Verisfield (Uk) Ltd. Σταθερες φαρμακευτικες συνθεσεις ιτρακοναζολης σευδατικο περιβαλλον
DE602005014393D1 (de) * 2005-03-28 2009-06-18 Dabur Pharma Ltd Stabile pharmazeutische zusammensetzungen aus antitumoralen platin-(ii)-mitteln
JP2009534409A (ja) * 2006-04-18 2009-09-24 イーケーアール セラピューティクス， インク． 予備混合即時使用静脈内ボーラス組成物および使用方法
EP2376062B1 (en) * 2008-12-26 2017-04-26 Samyang Biopharmaceuticals Corporation Preparation method of polymeric micellar nanoparticles composition containing a poorly water-soluble drug
KR101267813B1 (ko) * 2009-12-30 2013-06-04 주식회사 삼양바이오팜 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100560069B1 (ko) * 2002-11-29 2006-03-13 주식회사 태평양 생분해성 양친성 블록공중합체 및 이의 제조방법
KR100703872B1 (ko) * 2003-10-10 2007-04-09 주식회사 삼양사 양친성 블록 공중합체 및 이를 포함하는 약물 전달용고분자 조성물
KR100704548B1 (ko) * 2005-10-31 2007-04-09 한국과학기술연구원 염증 부위 특이적 고분자 유도체 및 그의 용도
KR20100057007A (ko) * 2007-07-09 2010-05-28 글렌 에스. 권 치료제의 마이셀 캡슐화

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SA-WON, LEE ET AL.: "Ionically fixed polymeric nanoparticles as a novel drug carrier", PHARMACEUTICAL RESEARCH, vol. 24, no. 8, 2007, pages 1508 - 1516, XP019507253 *

Also Published As

Publication number Publication date
KR101508275B1 (ko) 2015-04-08
EP2792348A4 (en) 2015-08-26
KR20130069197A (ko) 2013-06-26
EP2792348A2 (en) 2014-10-22
US9522190B2 (en) 2016-12-20
EP2792348B1 (en) 2020-10-14
CN104010627A (zh) 2014-08-27
US20140335194A1 (en) 2014-11-13
WO2013089394A2 (ko) 2013-06-20

Similar Documents

Publication Publication Date Title
WO2013089394A3 (ko) 고분자 나노입자 수용액 조성물 및 그 제조방법
CA2860973C (en) A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component.
WO2012153193A3 (en) Protein-active agent conjugates and method for preparing the same
MX2014004725A (es) Formulaciones de etanercept estabilizadas con aminoacidos.
WO2012121523A3 (en) Process for preparing pharmaceutical formulation in form of antioxidant-free solution for injection containing pemetrexed or its salt
JP2016014025A5 (ko)
WO2015152693A3 (ko) 신규 이중 나선 올리고 rna 및 이를 포함하는 섬유증 또는 호흡기 질환의 예방 또는 치료용 약학조성물
MX363380B (es) Formulacion de anticuerpos.
MX2019006221A (es) Preparacion de complejos solidos de ciclodextrina para suministro de ingredientes farmaceuticos activos oftalmicos.
WO2012076670A3 (en) Antibody formulation
PH12016501175A1 (en) Formulations of deoxycholic acid and salts thereof
WO2010140891A3 (en) Liquid enteral nutritional composition with a low monovalent metal ion content
WO2013114112A3 (en) Stabilized aqueous antibody compositions
WO2012100109A3 (en) Therapeutic eye drop comprising doxycycline and a stabilizer
BR112014009242A2 (pt) nanossuspensão farmacêutica
WO2012155226A8 (pt) Processo para a produção de derivados de pyrostegia venusta, derivados de pyrostegia venusta, composições farmacêuticas e seus usos
WO2013085422A3 (ru) Противотуберкулезная композиция и способ ее получения
MX371209B (es) Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz.
WO2012134187A3 (ko) 황반변성 예방 또는 치료용 약학 조성물
WO2011140305A3 (en) Method of producing pleurodesis
WO2010068181A8 (en) 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
WO2007025764A3 (de) Pharmazeutische formulierung für salze monobasischer säuren mit clopidogrel
EP2524701A3 (en) Pharmaceutical composition and method for producing the same
WO2014045307A3 (en) Pharmaceutical composition
WO2011013992A3 (en) R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and l-aspartic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same for antimicrobial

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12857983

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 14362234

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2012857983

Country of ref document: EP